Table 3. Prognostic information among models used in terms of OS.

OS	N of patients	N of events	CTS (8 df)		RRS (1 df)		AOS (1 df)		CTS+RRS (9 df)		CTS+AOS (9 df)		CTS+RRS vs. CTS (1 df)		CTS+AOS vs. CTS (1 df)
			LR-Δχ2	p	LR-Δχ2	p	LR-Δχ2	p	LR-Δχ2	p	LR-Δχ2	p	LR-Δχ2	p	LR-Δχ2	p
All patients	875	232	75.1	<0.001	4.4	0.036	75.3	<0.001	79.9	<0.001	96.0	<0.001	4.8	0.028	20.8	<0.001
By IHC subtype
Luminal A	201	32	19.1	0.008	4.5	0.034	10.7	0.001	25.2	0.002	26.3	0.001	6.1	0.013	7.2	0.007
Luminal B	313	86	31.0	<0.001	3.7	0.056	27.1	<0.001	35.9	<0.001	39.3	<0.001	4.8	0.028	8.3	0.004
Luminal-HER2	109	34	14.7	0.040	0.5	0.50	12.1	0.001	14.7	0.065	19.1	0.014	<0.1	0.91	4.4	0.035
HER2-Enriched	87	20	11.6	0.11	0.1	0.73	3.0	0.081	11.9	0.15	11.7	0.17	0.3	0.59	<0.1	0.90
Triple-negative	96	39	10.2	0.18	0.3	0.58	7.4	0.007	10.8	0.21	12.1	0.15	0.6	0.44	1.9	0.17
By HER2 status
HER2-positive	196	54	23.3	0.002	0.3	0.58	11.0	0.001	23.3	<0.001	24.8	0.002	<0.1	0.85	1.5	0.22
HER2-negative	621	161	53.3	<0.001	9.7	0.002	61.3	<0.001	61.9	<0.001	76.7	<0.001	8.7	0.003	23.4	<0.001
By nodal status (-1 df for CTS)
0–3	351	43	11.8	0.067	3.7	0.053	3.3	0.069	14.4	0.045	11.8	0.11	2.6	0.11	<0.1	0.91
>3	524	189	11.1	0.085	2.4	0.12	24.7	<0.001	13.8	0.054	35.0	<0.001	2.7	0.10	23.9	<0.001

For details on patient classification to breast cancer subtypes see footnote legend to Table 2.

OS, overall survival; N, number; CTS, clinical treatment score; RRS, risk for recurrence score; AOS, adjuvant online score; IHC, immunohistochemistry.